PTGS2 and osteosarcoma: We have previously shown that mavacoxib (TrocoxilTM), a clinically relevant COXIB in veterinary medicine, which is currently licenced to treat pain and inflammation in canine osteosarcoma, can exert anti-tumourigenic effects on a panel of canine cancer cell lines with low COX-2 expression indicating that this drug may act in a COX-2 independent manner (15).